{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:02:26Z","timestamp":1792087346742,"version":"4.4.0"},"reference-count":38,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"European Hematology Association"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Patient-reported outcomes (PROs) are becoming increasingly important in supporting clinical outcomes in clinical trials. In multiple myeloma (MM), PRO measurement is useful to reveal how treatment affects physical, psychosocial, and functional behaviour as well as symptoms and treatment-related adverse events to evaluate the benefit-risk ratio of a particular drug or drug combination. We report the types of PRO instruments used in MM, the frequency in which they are utilised in randomised controlled trials (RCTs), and the consistency of their reporting. Methods: The European Hematology Association (EHA) supports the development of guidelines for the use of PROs in adult patients with haematological malignancies. The first step is the present systematic review of the literature. MEDLINE and CENTRAL were searched for RCTs in MM between 2015 and 2020. Study design, characteristics of MM and its treatment, the primary outcomes, and the types of PRO instrument(s) were extracted using a predefined template. Additionally, in a stepwise approach, it was assessed whether the identified instruments had been validated for multiple myeloma patients, patients with haematological malignancies, or cancer patients. Results: Following screening for RCTs, 283 studies were included for review from 10,707 records retrieved, and 118 of these planned the use of PRO measures. Thirty-eight PRO instruments were reported. The most frequently used instrument (92 studies) was the EORTC QLQ-30. The EORTC-MY20 MM-specific questionnaire was the second most frequently used (50 studies), together with the EQ-5D (50 studies). Only 19 PRO instruments reported were consistent with the trial registry. Furthermore, in 58 publications, the information on PRO instruments differed between the publication and the trial registry. Further, information on PRO in HTA reports was available for 26 studies, of which 18 reports were consistent with the trial registries. Out of the 38 instruments used, six had been validated for patients with multiple myeloma (the most frequently used), six for patients with haematological malignancies, and 10 for cancer patients in general. Conclusions: The findings indicate that the measurement of PROs in RCTs for MM is underutilised, underreported, and often inconsistent. Guidelines for the appropriate use of PROs in MM are needed to ensure standardisation in selection and reporting. Furthermore, not all PRO instruments identified have been validated for myeloma patients or patients with haematological malignancies. Thus, guidelines for the appropriate use and reporting of PROs are needed in MM to ensure standardisation in the selection and reporting of PROs.<\/jats:p>","DOI":"10.3390\/cancers14236007","type":"journal-article","created":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T04:00:37Z","timestamp":1670385637000},"page":"6007","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["The Reporting, Use, and Validity of Patient-Reported Outcomes in Multiple Myeloma in Clinical Trials: A Systematic Literature Review"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4612-5699","authenticated-orcid":false,"given":"Sam","family":"Salek","sequence":"first","affiliation":[{"name":"School of Life and Medical Sciences, University of Hertfordshire, Hatfield AL10 9AB, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Ionova","sequence":"additional","affiliation":[{"name":"Quality of Life Monitoring Department, Saint-Petersburg State University Hospital, 190103 Saint-Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9238-5734","authenticated-orcid":false,"given":"Esther Natalie","family":"Oliva","sequence":"additional","affiliation":[{"name":"Grande Ospedale Metropolitano Bianchi Melacrino Morelli, 89124 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marike","family":"Andreas","sequence":"additional","affiliation":[{"name":"Evidence-Based Medicine, Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Skoetz","sequence":"additional","affiliation":[{"name":"Evidence-Based Medicine, Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8922-0488","authenticated-orcid":false,"given":"Nina","family":"Kreuzberger","sequence":"additional","affiliation":[{"name":"Evidence-Based Medicine, Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Laane","sequence":"additional","affiliation":[{"name":"Hematology-Oncology Clinic, Tartu University, 50406 Tartu, Estonia"},{"name":"Kuressaare Hospital, 93815 Kuressaare, Estonia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.6004\/jnccn.2022.0002","article-title":"NCCN Guidelines\u00ae Insights: Multiple Myeloma, Version 3.2022","volume":"20","author":"Callander","year":"2022","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(\u2020)","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and Management of Multiple Myeloma: A Review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1038\/leu.2012.113","article-title":"Multiple myeloma induces the immunosuppressive capacity of distinct myeloid-derived suppressor cell subpopulations in the bone marrow","volume":"26","author":"Schouppe","year":"2012","journal-title":"Leukemia"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"Ca Cancer J. Clin."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5419","DOI":"10.1158\/1078-0432.CCR-16-0625","article-title":"Progress and Paradigms in Multiple Myeloma","volume":"22","author":"Anderson","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"102284","DOI":"10.1016\/j.ctrv.2021.102284","article-title":"Roadmap to cure multiple myeloma","volume":"100","author":"Paiva","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"Pawlyn","year":"2021","journal-title":"Lancet"},{"key":"ref_9","unstructured":"Ota, F. (2021). Prognostic and Predictive Factors in Newly Diagnosed Multiple Myeloma Patients with Early Mortality with Prediction Matrix and Three and Five-Year Overall Survival. Multiple Myeloma, IntechOpen."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3816\/CLM.2005.n.045","article-title":"New approaches to treatment for multiple myeloma: Durable remission and quality of life as primary goals","volume":"6","author":"Durie","year":"2005","journal-title":"Clin. Lymphoma Myeloma"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41408-021-00432-4","article-title":"Management of patients with multiple myeloma beyond the clinical-trial setting: Understanding the balance between efficacy, safety and tolerability, and quality of life","volume":"11","author":"Terpos","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1600-0609.2009.01404.x","article-title":"What changes in health-related quality of life matter to multiple myeloma patients? A prospective study","volume":"84","author":"Kvam","year":"2010","journal-title":"Eur. J. Haematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/17474086.2019.1613886","article-title":"Quality of life in multiple myeloma: Considerations and recommendations","volume":"12","author":"Seitzler","year":"2019","journal-title":"Expert Rev. Hematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.6004\/jnccn.2020.7561","article-title":"Symptom Burden, Perceived Control, and Quality of Life Among Patients Living with Multiple Myeloma","volume":"18","author":"Zaleta","year":"2020","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/j.clml.2018.08.019","article-title":"Health-Related Quality of Life of Patients with Multiple Myeloma Treated in Routine Clinical Practice in France","volume":"19","author":"Touboul","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ejh.12882","article-title":"A systematic review of health-related quality of life in longitudinal studies of myeloma patients","volume":"99","author":"Nielsen","year":"2017","journal-title":"Eur. J. Haematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1200\/JCO.18.01006","article-title":"Patient-Reported Outcome Results from the Open-Label, Randomized Phase III Myeloma X Trial Evaluating Salvage Autologous Stem-Cell Transplantation in Relapsed Multiple Myeloma","volume":"37","author":"Ahmedzai","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12955-018-0953-4","article-title":"A prospective observational study to assess clinical decision-making, prognosis, quality of life and satisfaction with care in patients with relapsed\/refractory multiple myeloma: The CLARITY study protocol","volume":"16","author":"Efficace","year":"2018","journal-title":"Health Qual. Life Outcomes"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1080\/17474086.2019.1634541","article-title":"Quality of life outcomes in multiple myeloma patients: A summary of recent clinical trials","volume":"12","author":"Martino","year":"2019","journal-title":"Expert Rev. Hematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1080\/17474086.2019.1645005","article-title":"Towards the integration of patient-reported outcomes into the global clinical management of multiple myeloma","volume":"12","author":"Niscola","year":"2019","journal-title":"Expert Rev. Hematol."},{"key":"ref_21","unstructured":"Novik, A., Salek, S., and Ionova, T. (2012). Guidelines: Patient-Reported Outcomes in Hematology, European Hematology Association."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e267","DOI":"10.1016\/S1470-2045(18)30097-4","article-title":"Incorporating the patient experience into regulatory decision making in the USA, Europe, and Canada","volume":"19","author":"Kluetz","year":"2018","journal-title":"Lancet. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1182\/blood-2017-03-737403","article-title":"Patient-reported outcomes in hematology: Is it time to focus more on them in clinical trials and hematology practice?","volume":"130","author":"Efficace","year":"2017","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"792","DOI":"10.3324\/haematol.2016.142844","article-title":"Patient-centered research and practice in the era of genomics: A novel approach","volume":"101","author":"Salek","year":"2016","journal-title":"Haematologica"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/annonc\/mdv249","article-title":"A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)","volume":"26","author":"Cherny","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.clml.2022.01.009","article-title":"Patient-Reported Outcomes in Randomized Controlled Trials of Patients with Multiple Myeloma: A Systematic Literature Review of Studies Published Between 2014 and 2021","volume":"22","author":"Efficace","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41408-021-00543-y","article-title":"Review of patient-reported outcomes in multiple myeloma registrational trials: Highlighting areas for improvement","volume":"11","author":"Fernandes","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1600-0609.2009.01303.x","article-title":"Health-related quality of life assessment in randomised controlled trials in multiple myeloma: A critical review of methodology and impact on treatment recommendations","volume":"83","author":"Kvam","year":"2009","journal-title":"Eur. J. Haematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst. Rev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"84","DOI":"10.5195\/jmla.2017.111","article-title":"Reviewing retrieved references for inclusion in systematic reviews using EndNote","volume":"105","author":"Bramer","year":"2017","journal-title":"J. Med. Libr. Assoc."},{"key":"ref_31","unstructured":"(2022). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (Updated February 2022), Cochrane."},{"key":"ref_32","unstructured":"Higgins, J.P.T., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M.J., and Welch, V.A. (2022). Chapter 5: Collecting data. Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (Updated February 2022), Cochrane."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1046\/j.1365-2141.1996.352889.x","article-title":"Measurement of health-related quality of life in multiple myeloma. Nordic Myeloma Study Group","volume":"92","author":"Eika","year":"1996","journal-title":"Br. J. Haematol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.ejca.2007.04.022","article-title":"An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma","volume":"43","author":"Cocks","year":"2007","journal-title":"Eur. J. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1182\/blood-2018-99-113571","article-title":"The Relationship between Minimal Residual Disease and Patient Reported Outcomes in Relapsed\/Refractory Multiple Myeloma","volume":"132","author":"He","year":"2018","journal-title":"Blood"},{"key":"ref_37","first-page":"1121","article-title":"Clinical endpoints in oncology-a primer","volume":"11","author":"Delgado","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e18615","DOI":"10.1200\/JCO.2021.39.15_suppl.e18615","article-title":"Patient-reported outcomes in clinical trials for multiple myeloma: Where we are","volume":"39","author":"Andreas","year":"2021","journal-title":"J. Clin. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/23\/6007\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:34:55Z","timestamp":1760146495000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/23\/6007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,6]]},"references-count":38,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["cancers14236007"],"URL":"https:\/\/doi.org\/10.3390\/cancers14236007","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,6]]}}}